According to the outlet, New York-based Pfizer sold over-the-counter ranitidine drugs also known as Zantac from 1998 through 2006. In 2019, a small laboratory in Connecticut found that ranitidine ...

Zantac Litigation is Born “The best starting point involves a private company known as Valisure. Valisure theorized that ranitidine [aka Zantac] has the potential to degrade into a carcinogen known as ...

Plaintiffs had argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration ...

Plaintiffs argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked ...

The common claim in the lawsuits is that a contaminant in Zantac (ranitidine) called N-nitrosodimethylamine (NDMA) – as well as other ranitidine products – increased the risk of cancer.

These cases account for 93% of the Zantac (ranitidine) lawsuits currently pending against the company. Under these agreements, GSK will pay up to $2.2 billion to resolve the claims, contingent ...

The British Columbia Supreme Court has dismissed a proposed class action on behalf of users of ranitidine, who claimed that Zantac and other medicines containing ranitidine feature a carcinogen ...

GSK and rivals including Pfizer and Sanofi have been at the centre of a legal storm after Zantac was pulled from shelves in 2019 amid concerns an ingredient, ranitidine, caused cancer.

Settling the cases is not an admission of liability, the company said. Plaintiffs argued that the company knew that Zantac’s active ingredient, ranitidine, turned into the potential carcinogen NDMA ...